Human and murine ApoE markedly alters Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease

被引:252
作者
Fagan, AM [1 ]
Watson, M
Parsadanian, M
Bales, KR
Paul, SM
Holtzman, DM
机构
[1] Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA
[3] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46225 USA
[4] Indiana Univ Sch Med, Dept Pharmacol Toxicol & Psychiat, Indianapolis, IN 46225 USA
[5] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
关键词
D O I
10.1006/nbdi.2002.0483
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The epsilon4 allele of apolipoprotein E (apoE) is a risk factor for Alzheimer's disease (AD), perhaps through effects on amyloid-beta (Abeta) metabolism. Detailed analyses of various A,3 parameters in aging Abeta parameters in aging APP(V717F+/-) mice expressing mouse apoE, no apoE, or human apoE2, apoE3, or apoE4 demonstrate that apoE facilitates, but is not required for, Abeta fibril formation in vivo. Human apoE isoforms markedly delayed Abeta deposition relative to mouse apoE, with apoE2 (and apoE3 to a lesser extent) having a prolonged ability to prevent Abeta from converting into fibrillar forms. Isoform-specific effects of human apoE on Abeta levels and neuritic plaque formation mimicked that observed in AD (E4 > E3 > E2). Importantly, observation of an apoE-dependent decrease in percent soluble Abeta and enrichment of Abeta in membrane microdomains prior to Abeta deposition indicates that apoE influences Abeta metabolism early in the amyloidogenic process and provides a possible novel mechanism by which apoE affects AD pathogenesis. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:305 / 318
页数:14
相关论文
共 73 条
  • [51] APOLIPOPROTEIN-E - HIGH-AVIDITY BINDING TO BETA-AMYLOID AND INCREASED FREQUENCY OF TYPE-4 ALLELE IN LATE-ONSET FAMILIAL ALZHEIMER-DISEASE
    STRITTMATTER, WJ
    SAUNDERS, AM
    SCHMECHEL, D
    PERICAKVANCE, M
    ENGHILD, J
    SALVESEN, GS
    ROSES, AD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (05) : 1977 - 1981
  • [52] Sun YL, 1998, J NEUROSCI, V18, P3261
  • [53] Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome
    Teller, JK
    Russo, C
    DeBusk, LM
    Angelini, G
    Zaccheo, D
    DagnaBricarelli, F
    Scartezzini, P
    Bertolini, S
    Mann, DMA
    Tabaton, M
    Gambetti, P
    [J]. NATURE MEDICINE, 1996, 2 (01) : 93 - 95
  • [54] Teter B, 2000, ALZHEIMERS REP, V3, P199
  • [55] Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein
    Trommsdorff, R
    Borg, JP
    Margolis, B
    Herz, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (50) : 33556 - 33560
  • [56] Modulation of β-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP) -: Evidence that LRP contributes to the pathogenesis of Alzheimer's disease
    Ulery, PG
    Beers, J
    Mikhailenko, I
    Tanzi, RE
    Rebeck, GW
    Hyman, BT
    Strickland, DK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (10) : 7410 - 7415
  • [57] Urmoneit B, 1997, LAB INVEST, V77, P157
  • [58] Astrocytes down-regulate neuronal β-amyloid precursor protein expression and modify its processing in an apolipoprotein E isoform-specific manner
    Vincent, B
    Smith, JD
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2001, 14 (02) : 256 - 266
  • [59] Cholesterol-dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains
    Wahrle, S
    Das, P
    Nyborg, AC
    McLendon, C
    Shoji, M
    Kawarabayashi, T
    Younkin, LH
    Younkin, SG
    Golde, TE
    [J]. NEUROBIOLOGY OF DISEASE, 2002, 9 (01) : 11 - 23
  • [60] The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging
    Wang, J
    Dickson, DW
    Trojanowski, JQ
    Lee, VMY
    [J]. EXPERIMENTAL NEUROLOGY, 1999, 158 (02) : 328 - 337